Grosse Chance WKN 931506

Seite 2 von 14
Neuester Beitrag: 02.05.10 14:39
Eröffnet am: 04.04.07 09:33 von: plusquamperf. Anzahl Beiträge: 342
Neuester Beitrag: 02.05.10 14:39 von: _bbb_ Leser gesamt: 25.025
Forum: Hot-Stocks   Leser heute: 1
Bewertet mit:

Seite: < 1 |
| 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 14  >  

366 Postings, 5111 Tage TheInvestmentbanke.$$über 80.000 Stücke gerade in America$$

23.04.07 17:30
hier will ein grosser rein und das ist auch gut so :-))
sehr guter Umsatze heute  

6795 Postings, 5269 Tage plusquamperfektHaltet den Kurs oben, muss leider

23.04.07 17:32
mal bissle weg  

366 Postings, 5111 Tage TheInvestmentbanke.@plus

23.04.07 17:34
wenn du wieder da bist stehen wir bei 0,19$ hoffe ich
gerade wieder grosser Kauf in Übersee....  

6795 Postings, 5269 Tage plusquamperfektRT USA 0,184 Sie steigt weiter

24.04.07 16:41
Angehängte Grafik:

199 Postings, 5793 Tage kinu+222% weitermachen

02.10.07 17:00

1859 Postings, 7563 Tage karibikRT USA

02.10.07 21:14
bei 0,28 nach merger news  

1859 Postings, 7563 Tage karibikmerger news

02.10.07 21:14
Genesis Technology Group Merges With Chinese Pharmaceutical: 'Crowning Achievement' Says Management
BOCA RATON, Fla., Oct. 2, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTCBB:GTEC) has entered into a reverse merger with a company that owns and controls Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("LJPC"), a Chinese pharmaceutical company. For its fiscal year ended June 30, 2007, the Company reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000.

Located in a coastal city in Shandong Province, LJPC underwent an official audit by Moore Stephens Wurth Frazer and Torbet, LLP of Los Angeles, California, in addition to a rigorous due diligence process by Genesis management and consultants.

Based on research performed by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City last month, revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period.

Mr. Gary L. Wolfson, Genesis CEO since August 2002, reported: "Since early 2003, Genesis management has earnestly and methodically sought a merger partner. Under the guidance of Dr. Shaohua Tan in China, we screened numerous candidates, and none could match the strength and potential of Laiyang Jiangbo Pharmaceuticals.

"It is an honor to turn over the future of the merged company to the leadership of Mr. Wubo Cao and his experienced team. Mr. Cao shall serve as the Chairman and Chief Executive Officer. It is our belief that the existing Genesis shareholders will be rewarded for their patience and dedication. In many ways, this merger is the crowning achievement of many years of effort and planning by Genesis management.

"The details of the merger will be explained fully in filings with the Securities & Exchange Commission and in a letter to be posted on our website," explained Mr. Wolfson.

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. (d/b/a Genesis China and GTEC) is a U.S. public company that partners with qualified Chinese companies to expand their domestic and international market opportunities. The customized private-to-public program seeks to tap in to Western capital markets to attain this goal. Commitment, dedication, and expertise are the key components to the Genesis "Mission Statement." It has created a successful profit center by incubating Chinese companies in a wide range of sectors, creating so-coined "partner companies." Genesis makes a long-term commitment with management consultation, board of directors' composition, creation and implementation of successful business models, which include expansion of markets in China and abroad. To help drive the success and profitability of these operations, Genesis provides resources and proficiency to maximize partners' leadership potential in China and attempts to increase high-margin, predictable earnings. The forgoing description is prior to completion of the merger, which has resulted in Genesis Pharmaceutical Enterprises, Inc., the name of the merged company. For more information, visit

Safe Harbor Statement and Disclaimer

Certain statements set forth in this press release constitute "forward-looking statements". Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission. The capital and growth program, the Company's central profit center, has specific risks and liabilities. Followers of our business model must understand that, until the Chinese partner company officially reaches public company status and files its initial Form 8-K, a high degree of risk exists that the partner may not ever attain that status. While receipt of a significant equity position in these companies is contractual, Genesis still recognizes that such compensation is conditional on performance and specific deliverables.

CONTACT:  Genesis Pharmaceutical Enterprises, Inc.
         Elsa Sung, Chief Financial Officer
         (800) 867-0078, ext. 602
         Fax: (561) 988-9890
         7900 Glades Road, Suite 420
         Boca Raton, Florida 33434

Source: PrimeNewswire (October 2, 2007 - 8:34 AM EST)

News by QuoteMedia  

6795 Postings, 5269 Tage plusquamperfektSchön

08.10.07 16:20
Angehängte Grafik:

6795 Postings, 5269 Tage plusquamperfektSchlecht

08.10.07 17:54
Angehängte Grafik:

6795 Postings, 5269 Tage plusquamperfektBesser

08.10.07 18:20
Angehängte Grafik:

6795 Postings, 5269 Tage plusquamperfektRT 0,28

12.10.07 16:28

4951 Postings, 4729 Tage 0815axallen hier investierten

13.10.07 15:47
...viel Erfolg in der(n) nächsten Wochen(n).
Wird Zeit, dass die Rakete zündet!
8K draussen - Zahlen mMn sehr gut ==> also 5-4-3-2-1 goooooooooo...  

2276 Postings, 6508 Tage duffyduck2 fragen zu genesis

17.10.07 09:59
1; warum ist der handel in deutschland so gering in usa eigentlich recht nett.
2; was müsste für eine meldung kommen (bzw. wäre vorstellbar) um noch einen hype auszulosen. ich kenn mich mit den reverse merger nicht so aus. was ist da an meldung möglich.  

6795 Postings, 5269 Tage plusquamperfektNEWS

17.10.07 15:13

Genesis Technology Group Releases Partner Company's 2007 Audited Annual Report
Wednesday October 17, 7:00 am ET

BOCA RATON, Fla., Oct. 17, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News), to be known as Genesis Pharmaceutical Enterprises, Inc. through a recently-completed merger, released the audited annual report from one its former partner companies: Speedhaul Holdings, Inc. (OTC BB:SPEH.OB - News).
Speedhaul Holdings, to be known as Gold Horse International, Inc., and Lotus Pharmaceuticals, Inc. (OTC BB:LTUS.OB - News) represent residual holdings that Genesis manages on behalf of its shareholders. The private-to-public program is no longer an ongoing profit center for Genesis Pharmaceutical Enterprises, Inc.


Yesterday, Speedhaul Holdings released its 2007 Annual Report, for the fiscal year ended June 30th, showing revenues of $28.3 million, net profits of $2.6 million, and net assets of $15.37 million. Year-to-year, net revenues increased 25.3%, and net income increased 55.5%. Kabani & Company of Los Angeles, California conducted the Company's audit.

Mr. Adam Wasserman, Speedhaul Chief Financial Officer, summarized the Company's year-to-year performance: ``For the year ended June 30, 2007, net revenues amounted to $28,322,306 compared to $22,608,755 for the year ended June 30, 2006, an increase of $5,713,551 or 25.3%. Additionally, for the year ended June 30, 2007, net income amounted to $2,594,526 as compared $1,668,699, an increase of $1,409,247 or 55.5%. For the years ended June 30, 2007 and 2006, net income per common shares was $.05 and $.03, respectively.''

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. (to be known as Genesis Pharmaceutical Enterprises, Inc.) is a U.S. public company engaged in research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province and is one of the major pharmaceutical companies in China producing tablets, capsules, and granules for both Western medical drugs and Chinese herbal-based medical drugs. The Company maintains a representative office in the United States of America, where its Chief Financial Officer and support staff are located. For more information, refer to  

6795 Postings, 5269 Tage plusquamperfektWas wird das heut ?

17.10.07 16:57
Angehängte Grafik:

6795 Postings, 5269 Tage plusquamperfektUnglaublich

18.10.07 17:47
da schmeissen die Deutschen zu 0,186 Euro bei einer Parität von 0,21 Euro

Times & Sales
   Uhrzeit      Kurs§letztes Volumen kumuliert
  16:16:19      0,20     5.000   104.634          §
  16:16:13     0,186    10.000    99.634          §
  16:15:45      0,20     5.100    89.634          §
  15:59:30     0,204     5.000    84.534          §
  15:45:13     0,201     7.000    79.534          §
  14:59:31     0,208     4.000    72.534          §
  14:53:26      0,21    10.000    68.534          §
  13:44:48      0,21    30.000    58.534          §
  13:44:26     0,212    11.534    28.534          §
  11:39:09     0,206    12.000    17.000          §
  09:03:25     0,222     5.000§5.000  

2276 Postings, 6508 Tage duffyduckund das noch bei sehr wenig umsatz

18.10.07 18:51
und nach den guten vorzeichen, dass es weiter aufwärts gehen könnte  

6795 Postings, 5269 Tage plusquamperfektjepp die will eher hoch als runter

18.10.07 19:15
Angehängte Grafik:

6795 Postings, 5269 Tage plusquamperfektGuter Schluss gestern in den USA

23.10.07 09:07
der auf einen heutigen Anstieg hoffen lässt

Angehängte Grafik:

4951 Postings, 4729 Tage 0815axNews 24.10.07 (engl)

24.10.07 18:32

2276 Postings, 6508 Tage duffyduckkomisch bei genesis wird kaum in deutschland

24.10.07 22:08
gehandelt. dafür steigt aber das ding im gegensatz zu vielen anderen bei denen es umgekehrt ist(siehe meine upda....)
aber wenigstens rennt die.  

6795 Postings, 5269 Tage plusquamperfektWow

25.10.07 09:04
Angehängte Grafik:

6795 Postings, 5269 Tage plusquamperfektT+S OTCBB

25.10.07 09:14
Time & Sales  
          §Price Size     Exch Time
  0.349 5000     OBB 15:58:29
  0.349 5000     OBB 15:57:28
  0.35 15000     OBB 15:56:57
  0.35 9000     OBB 15:56:47
  0.349 20000     OBB 15:56:16
  0.349 10000     OBB 15:56:10
  0.349 5500     OBB 15:56:06
  0.345 200     OBB 15:56:06  

6795 Postings, 5269 Tage plusquamperfektRT 0,222 Euro

25.10.07 09:17

6795 Postings, 5269 Tage plusquamperfektRT 0,232

25.10.07 09:19

Seite: < 1 |
| 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 14  >  
   Antwort einfügen - nach oben